In the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claim 1. (Original) Fexofenadine hydrochloride characterized by a PXRD pattern with peaks at about 4.7, 9.3, 17.4, 18.2, 19.4, 19.6, 21.6 and 24.0±0.2 degrees two theta.

Claim 2. (Original) The fexofenadine hydrochloride of claim 1 having a PXRD pattern substantially as depicted in Fig. 6.

Claim 3. (Original) Fexofenadine hydrochloride Form IX.

Claim 4. (Original) A fexofenadine hydrochloride MTBE solvate.

Claim 5. (Original) A fexofenadine hydrochloride Form IX-MTBE solvate.

Claim 6. (Original) A fexofenadine hydrochloride MTBE solvate characterized by a DTG profile with endotherms at about 100°C and about 125°C.

Claims 7 – 9 (cancelled).

Claim 10. (Original) A process for preparing fexofenadine hydrochloride Form IX comprising the steps of:

a) preparing a solution of fexofenadine hydrochloride in acetone;

b) adding the solution to an anti-solvent selected from the group consisting of MTBE and cyclohexane to form a precipitate; and

c) separating the precipitate as a solvate of the anti-solvent used.

Claim 11. (Original) The process of claim 10, further comprising drying the solvate.

Claim 12. (Original) A process for preparing fexofenadine hydrochloride Form IX comprising the steps of:

a) preparing a solution of fexofenadine hydrochloride in ethanol;

b) adding the solution to an anti-solvent selected from the group consisting of MTBE and cyclohexane to form a precipitate; and

c) separating the precipitate as a solvate of the anti-solvent used.

Claim 13. (Original) The process of claim 12, further comprising drying the solvate.

Claim 14. (Original) A pharmaceutical composition comprising:

a) fexofenadine hydrochloride selected from the group consisting of Form IX-MTBE solvate and Form IX-cyclohexane solvate; and

b) a pharmaceutically acceptable excipient.

Claim 15. (Original) A unit dosage of the pharmaceutical composition of claim 14 containing about 30 to about 180 mg of fexofenadine hydrochloride.

Claim 16. (Original) A method of inhibiting binding between an H1 receptor and histamine in a mammal comprising administering the pharmaceutical composition of claim 14 to the mammal.